ライフサイエンスコーパス: ivermectin

1 orm infection were 57% (moxidectin) and 56% (ivermectin).

2 glycine, or glycine and ivermectin (glycine/ivermectin).

3 and following treatment with parasiticides (ivermectin).

4 t serve as an alternative to the widely used ivermectin.

5 for moxidectin compared to 95.2% (59/62) for ivermectin.

6 annual or 3-monthly (quarterly) exposures to ivermectin.

7 d for 3 days after a single systemic dose of ivermectin.

8 n prevalence by mass distribution of donated ivermectin.

9 hieved in some areas following many years of ivermectin.

10 d current and was modulated significantly by ivermectin.

11 wed desensitization and was not modulated by ivermectin.

12 ctures of C. elegans GluCl in the absence of ivermectin.

13 se to the P2X4R-specific allosteric enhancer ivermectin.

14 lexed with the positive allosteric modulator ivermectin.

15 ectin starting from the structure with bound ivermectin.

16 eported to be successfully treated with oral ivermectin.

17 e patient was treated successfully with oral ivermectin.

18 laricidal and possibly sterilizing effect of ivermectin.

19 s are the site of action of the anthelmintic ivermectin.

20 h-level resistance to the antiparasitic drug ivermectin.

21 se in the affinity for nodulisporic acid and ivermectin.

22 to receive placebo or standard- or high-dose ivermectin.

23 2025, accounting for the impact of MDA with ivermectin.

24 glutamate-gated chloride channels similar to ivermectin.

25 potentiation by the known positive modulator ivermectin.

26 to one dose (n=155) or four doses (n=154) of ivermectin.

27 r L loa microfilaraemia before being offered ivermectin.

28 y Cu(2+), and the P2X4 modulators Zn(2+) and ivermectin (0.3-3 microM) each increased intracellular [

29 Oral ivermectin, 12 mg, was given, and the eruption cleared w

30 0 cm in height received single oral doses of ivermectin (150-200 mug/kg) and albendazole (400 mg), an

31 se of ivermectin 200 mug/kg or four doses of ivermectin 200 mug/kg (given on days 1, 2, 15, and 16).

32 participants were offered two doses of oral ivermectin 200 mug/kg 7-14 days apart using weight-based

33 participants) to receive either one dose of ivermectin 200 mug/kg or four doses of ivermectin 200 mu

34 total) from Manaus, Brazil, with single-dose ivermectin (200 microg/kg).

35 efficacy and safety of moxidectin (8 mg) vs ivermectin (200 mug/kg) against S. stercoralis infection

36 were treated with a single oral dose of IDA (ivermectin, 200 mug/kg; diethylcarbamazine, 6 mg/kg; plu

37 P2X4 receptor-selective allosteric enhancer ivermectin (3 microM), the 2-meSATP-stimulated current i

38 icated malaria in Kenya, comparing 3 days of ivermectin 300 mcg/kg/day, ivermectin 600 mcg/kg/day, or

39 testing, a total of 15,522 (95.5%) received ivermectin, 340 (2.1%) were excluded from ivermectin dis

40 Ivermectin, 4-vynilpiridine and ethylene glycol dimethac

41 mparing 3 days of ivermectin 300 mcg/kg/day, ivermectin 600 mcg/kg/day, or placebo, all co-administer

42 proaches to include the mass distribution of ivermectin - a drug donated by Merck & Co. for disease c

43 This formulation is designed to release ivermectin, a mosquito-killing drug for 10 days after a

44 The compounds considered are ivermectin, abamectin, emamectin, eprinomectin, doramect

45 Treatment with a single dose of oral ivermectin achieved resolution of her symptoms.

46 resulted in similar mosquitocidal effects of ivermectin across a wide range of drug concentrations, s

47 g direct evidence that nodulisporic acid and ivermectin act on DmGluClalpha channels.

48 these individuals may be excluded from mass ivermectin administration campaigns against onchocercias

49 in children aged <10 years for stopping mass ivermectin administration.

50 ld and 10-fold higher in vitro activity than ivermectin against hepatic and blood stage infections, r

51 a single or repeated dose (200 microg/kg) of ivermectin (AL-IVM1 and AL-IVM2, respectively).

52 g yaws and trachoma, with the newly approved ivermectin, albendazole, diethylcarbamazine (IDA) regime

53 hs following treatment with a single dose of ivermectin-albendazole, some of these defects were rever

54 vention group received five further doses of ivermectin alone at 3-week intervals thereafter over the

55 scabies and impetigo prevalence compared to ivermectin alone.

56 At higher concentrations, ivermectin also acts as an allosteric modulator of ion c

57 Our results demonstrate that ivermectin, an FDA-approved antiparasitic agent, is effe

58 Treatment with ivermectin, an importin inhibitor, blocked HE4/importin-

59 was a sustained impact of a single round of ivermectin and azithromycin mass drug coadministration o

60 on Islands 36 months after a single round of ivermectin and azithromycin mass drug coadministration.

61 of large-scale mass coadministration of oral ivermectin and azithromycin, which have been previously

62 ed to inform other studies on anthelmintics (ivermectin and emodepside) that act on ion channels.

63 x was determined with the allosteric agonist ivermectin and in additional structures with the endogen

64 cyclic lactones (ML) (abamectin, doramectin, ivermectin and moxidectin) in butter, using liquid chrom

65 (MLs) (abamectin, doramectin, eprinomectin, ivermectin and moxidectin) in cheese.

66 reatments for young children, including with ivermectin and moxidectin, should be investigated.

67 pha antibodies immunoprecipitated all of the ivermectin and nodulisporic acid receptors solubilized b

68 In the near future, ivermectin and other endectocides could serve as potent

69 nd channel block, and the mechanism by which ivermectin and related molecules stabilize the open stat

70 activation by nodulisporic acid, as well as ivermectin and the endogenous ligand glutamate, providin

71 nistrations, potentially in combination with ivermectin and vaccination, mass screening and treatment

72 treat filariasis include diethylcarbamazine, ivermectin, and albendazole, which are used mostly in co

73 hese two ligands was modulated by glutamate, ivermectin, and antagonists of invertebrate gamma-aminob

74 d 3-fold cross-resistant to the parasiticide ivermectin, and exhibited decreased brood size, decrease

75 alciparum infection, suggesting inclusion of ivermectin antimalarial hybrids in malaria control strat

76 atment on blood from pooled patients in both ivermectin arms was similar with direct skin feeding (mo

77 There are limited data on the activity of ivermectin as a topical lousicide.

78 (399 pregnancy outcomes) purposely received ivermectin as part of the open-label RCT.

79 esults revealed the cytotoxins etoposide and ivermectin as potent inducers, allowing us to isolate an

80 that topical brimonidine, azelaic acid, and ivermectin, as well as oral doxycycline and isotretinoin

81 sociated with the initiation and severity of ivermectin-associated adverse reactions.

82 rrogate the inflammatory etiology of loiasis ivermectin-associated adverse reactions.

83 lly, positive allosteric modulation of P2X4 (ivermectin) augmented ATP-mediated CXCL5 secretion.

84 Ivermectin based mass drug administration (MDA) reduces

85 Implementation of an ivermectin-based community treatment strategy for the el

86 Ivermectin-based mass drug administration can be scaled

87 Ivermectin-based mass drug administration has emerged as

88 ed to receive either ivermectin-based MDA or ivermectin-based MDA co-administered with azithromycin.

89 ommunities were randomized to receive either ivermectin-based MDA or ivermectin-based MDA co-administ

90 idiasis, but required a course of parenteral ivermectin because of malabsorption from severe gastroin

91 It increased the K(d) for radiolabeled ivermectin binding from 0.35 +/- 0.1 to 2.26 +/- 0.78 nM

92 Ivermectin binding was composed of at least two kinetica

93 produced no detectable channel activity, but ivermectin binding was similar to wild-type.

94 ) had no effect on l-glutamate activation or ivermectin binding: one (T300S) produced no detectable c

95 revent pumping, in the absence of the AVR-15 ivermectin-binding channel on pharynx muscle, is to targ

96 P2X4, the lysosomal P2X4 was potentiated by ivermectin but insensitive to suramin and PPADS, and it

97 Ivermectin but not benzimidazole treatments induce rapid

98 nel modified to be activated by low doses of ivermectin (but not glutamate) is highly effective in si

99 nce for an interaction with ketoconazole and ivermectin, but not thiabendazole.

100 s study expands our mechanistic knowledge of ivermectin by showing that ivermectin targets the abilit

101 However, ivermectin can also inhibit pumping in the absence of th

102 In such cases, treatment with ivermectin can be beneficial.

103 This study indicates that parenteral ivermectin can be used safely and effectively in patient

104 sis in areas where loiasis is co-endemic and ivermectin cannot be safely mass administered.

105 ns may lead to higher mosquito mortality, as ivermectin capillary concentrations are higher.

106 by body mass index, and across the range of ivermectin capillary concentrations studied (0.72-73.9 n

107 on through community-directed treatment with ivermectin (CDTI) in Central Africa.

108 omprehensive multiple-dose clinical trial of ivermectin, comparing 3-monthly with annual treatments a

109 st-bound open channel state, and the glycine/ivermectin complex adopts a potentially desensitized or

110 in a variety of systems, we question whether ivermectin could have additional modes of action on para

111 We propose that one of the ways ivermectin could prevent pumping, in the absence of the

112 Treatment with either albendazole or ivermectin cured all patients with most responding withi

113 maximal ivermectin response, indicating that ivermectin depolarizes the muscle by the same ionic mech

114 Here we tell the story of ivermectin, describing its anthelmintic and insecticidal

115 Multiple doses of ivermectin did not show higher efficacy and was tolerate

116 However, one dose of a triple-drug regimen (ivermectin, diethylcarbamazine, and albendazole) has bee

117 Ivermectin directly binds this pocket to inhibit MAPKAP2

118 Mechanistically, we show that ivermectin disrupts binding of the viral E1A protein to

119 ed ivermectin, 340 (2.1%) were excluded from ivermectin distribution because of an L. loa microfilari

120 abled the reimplementation of community-wide ivermectin distribution in a heretofore "off limits" hea

121 Switching from annual to biannual ivermectin distribution may accelerate progress toward t

122 utic or preventative modality (separate from ivermectin distribution or vector control), elimination

123 al African countries have adopted a biannual ivermectin distribution strategy in some foci to control

124 erious adverse events, and exclude them from ivermectin distribution.

125 ted severe posttreatment reactions following ivermectin distribution.

126 Individuals treated with ivermectin do not need to be retested for L loa microfil

127 crucially depends on the effects of multiple ivermectin doses on Onchocerca volvulus.

128 It is unclear whether exposure to ivermectin during pregnancy increases the risk of sponta

129 vidence to conclude on the safety profile of ivermectin during pregnancy.

130 Frequently repeated mass administrations of ivermectin during the malaria transmission season can re

131 channels responded to low concentrations of ivermectin (estimated EC(50) = approximately 0.1 +/- 1.0

132 serious and non-serious adverse events after ivermectin exposure in pregnant women.

133 ress this question, 14 patients treated with ivermectin for onchocerciasis acquired >10 years ago dur

134 the efficacy of mass drug administration of ivermectin for scabies and impetigo, with coadministrati

135 ecent studies that have sought to reposition ivermectin for the treatment of other diseases that are

136 ght be a safe and efficacious alternative to ivermectin for the treatment of S. stercoralis infection

137 Samples, fortified with ivermectin from 50 to 500 mug kg(-1), were used to build

138 haracterized and used for direct analysis of ivermectin from bovine meat samples, in a two-dimensiona

139 lyR with strychnine, glycine, or glycine and ivermectin (glycine/ivermectin).

140 CI, 35 to 73), and from 24.6% to 8.0% in the ivermectin group (relative reduction, 67%; 95% CI, 52 to

141 CI, 49 to 75), and from 32.1% to 1.9% in the ivermectin group (relative reduction, 94%; 95% CI, 83 to

142 ild and were reported more frequently in the ivermectin group than in the permethrin group (15.6% vs.

143 roup), or mass administration of ivermectin (ivermectin group).

144 In the ivermectin group, there was a significant correlation be

145 ups, with the greatest reduction seen in the ivermectin group.

146 ups, with the greatest reduction seen in the ivermectin group.

147 532 in the permethrin group, and 716 in the ivermectin group.

148 WT mice treated with P2X4 allosteric agonist ivermectin had exacerbated renal IR injury whereas P2X4

149 Ivermectin has been on the veterinary market for almost

150 ty-based trials, mass drug administration of ivermectin has been shown to substantially decrease the

151 th the growing body of literature suggesting ivermectin has broad antiviral activity.

152 Ivermectin has controlled transmission of microfilariae,

153 pite this promise, the antiviral activity of ivermectin has not been consistently proven in vivo.

154 The discovery of the drug ivermectin has provided humankind with a powerful new me

155 Multiple doses of ivermectin have a partial macrofilaricidal and a modest

156 About 3.7 billion doses of ivermectin have been distributed in mass drug administra

157 pproved drug available for mass treatment is ivermectin, however, drug resistance is beginning to eme

158 81 (>99.9%) of 6983 individuals treated with ivermectin in 2015 had L loa microfilariae density below

159 The efficacy of ivermectin in ameliorating behavioural hypersensitivity

160 e found in samples of bovine muscle and only ivermectin in bovine liver.

161 o monitoring withdrawal period specified for ivermectin in cattle.

162 Severe adverse events after treatment with ivermectin in individuals with high levels of Loa loa mi

163 we discuss challenges surrounding the use of ivermectin in the context of coronavirus disease-19 (COV

164 ependently by three approaches: analogy with ivermectin in the GluCl crystal structure, automated doc

165 nant women (500 pregnancy outcomes) received ivermectin inadvertently during MDA campaigns in the obs

166 3)-mediated event and was not potentiated by ivermectin, indicating that these responses were not P2X

167 Finally, P2X4 agonist ivermectin induced NLRP3 inflammasome and pro-inflammato

168 Similarly, ivermectin inhibits genome replication of HAdV-B3, a cli

169 In this study, we show that ivermectin inhibits HAdV-C5 early gene transcription, ea

170 l effect on mosquito vectors of the disease, ivermectin inhibits Plasmodium falciparum sporogonic and

171 0-100 times higher than current human doses, ivermectin is a known teratogen in mammals.

172 Ivermectin is a powerful endectocide, which reduces the

173 Ivermectin is an FDA-approved broad-spectrum antiparasit

174 Ivermectin is an FDA-approved broad-spectrum antiparasit

175 hocerciasis with diethylcarbamazine (DEC) or ivermectin is associated with a posttreatment reaction c

176 Ivermectin is being considered for mass drug administrat

177 The nematocidal drug ivermectin is believed to kill worms by opening a glutam

178 field of veterinary medicine, resistance to ivermectin is now widespread, but the mechanisms underly

179 Ivermectin is one of the most important drugs in veterin

180 Mass drug administration (MDA) with ivermectin is the cornerstone of efforts to eliminate hu

181 Ivermectin is the drug of choice for the treatment of S

182 Ivermectin is widely used in mass drug administrations f

183 permethrin group), or mass administration of ivermectin (ivermectin group).

184 Ivermectin (IVM) has been the drug of choice for the tre

185 The endectocide ivermectin (IVM) induces a similar, but larger current t

186 We show that ivermectin (IVM) is a specific positive allosteric effec

187 Ivermectin (IVM) is widely used in both human and veteri

188 Ivermectin (IVM) may reduce malaria transmission by kill

189 eceptors is the presence of the large ligand ivermectin (IVM) positioned between all five subunits.

190 lRs) are ion channels serving as targets for ivermectin (IVM), a broad-spectrum anthelmintic drug use

191 inding sites and allosterically regulated by ivermectin (IVM), a broad-spectrum antiparasitic agent.

192 Ivermectin (Ivm), a glycine receptor (GLR) agonist, was

193 We probed these motions using ivermectin (IVM), a macrocyclic lactone that stabilizes

194 antifilarial drugs diethylcarbamazine (DEC), ivermectin (IVM), and albendazole (ALB) for LF are unkno

195 Ivermectin (IVM), used alongside mass treatment strategi

196 ne (DEC), the drug of choice for loiasis, or ivermectin (IVM), which is used in mass drug administrat

197 lly in mouse striatum a modified heteromeric ivermectin (IVM)-gated chloride channel from C. elegans

198 We express invertebrate ivermectin (IVM)-sensitive chloride channels (Caenorhabd

199 urons upon exposure to the anthelmintic drug ivermectin (IVM).

200 whether annual or semiannual treatment with ivermectin (IVM; 200 ug/kg) plus albendazole (ALB; 800 m

201 whether annual or semiannual treatment with ivermectin (IVM; 200ug/kg) plus albendazole (ALB; 800mg

202 ubsequent protein exocytosis was enhanced by ivermectin (IVR).

203 Co-administration of azithromycin with ivermectin led to similar decreases in scabies and impet

204 from widely used anthelmintic drugs such as ivermectin, levamisole, and aldicarb, representing a pot

205 es, we compared a single application of 0.5% ivermectin lotion with vehicle control for the eliminati

206 The azithromycin ivermectin mass drug administration (AIM) trial was a pr

207 ng a bead-based immunoassay before and after ivermectin mass drug administration (MDA) for scabies in

208 Multiple doses of ivermectin may cumulatively and permanently reduce the f

209 .019), demonstrating collateral benefits of ivermectin MDA in this setting.

210 ur, 12 and 21 months after microfilaricidal (ivermectin, n = four), macrofilaricidal (doxycycline, n

211 brane pore markedly attenuates the effect of ivermectin on Ca(2+) current and channel gating.

212 To assess the effect of ivermectin on the morbidity caused by hookworm-related c

213 The potency of ivermectin on the pharynx was greater than at any of the

214 evalences had fallen to 1.0% and 2.5% in the ivermectin-only arm and 0.7% and 3.3% in the combined tr

215 tigo prevalences were 11.8% and 10.1% in the ivermectin-only arm and 9.2% and 12.1% in the combined t

216 A tube of topical ivermectin or vehicle control was dispensed on day 1, to

217 of this strategy and quantified responses to ivermectin over 2 consecutive rounds of treatment in 10

218 For ivermectin, participants were offered two doses of oral

219 DA) is non-inferior to three annual doses of ivermectin plus albendazole (IA) used in many LF endemic

220 is noninferior to standard 3 annual doses of ivermectin plus albendazole (IA) used in many LF-endemic

221 nt strategy of mass drug administration with ivermectin plus albendazole for lymphatic filariasis can

222 ned whether a single co-administered dose of ivermectin plus diethylcarbamazine plus albendazole [IDA

223 inistered dose of a new triple drug regimen (ivermectin plus diethylcarbamazine plus albendazole, IDA

224 hR evoked by PAMs, including potentiation by ivermectin, PNU-120596, and TQS, as well as activation b

225 Ivermectin potentiated activity of anti-androgen recepto

226 0 also effectively suppresses ATP-evoked and ivermectin-potentiated membrane permeabilization induced

227 Ivermectin potently and irreversibly depolarized the mus

228 therapy for onchocerciasis with intermittent ivermectin prevents the development of pathology in ende

229 Because solubilized nodulisporic acid and ivermectin receptors comigrated as 230-kDa complexes by

230 d that there also exists a distinct class of ivermectin receptors that contains the DmGluCl alpha sub

231 mRdl are components of nodulisporic acid and ivermectin receptors, and that there also exists a disti

232 receptors, but only approximately 70% of the ivermectin receptors.

233 rily through the mass drug administration of ivermectin, remains challenging and has been heightened

234 The trajectory of GluCl with ivermectin removed shows a sequence of structural events

235 ch thresholds even within 50 years of annual ivermectin, requiring adoption of biannual treatment.

236 some candidate genes that may play a role in ivermectin resistance.

237 tion of maximal glutamate during the maximal ivermectin response, indicating that ivermectin depolari

238 The insecticide ivermectin reversibly activated homomeric HisCl1 channel

239 zole for T. trichiura, including albendazole-ivermectin (RR of cure, 3.22 [95% confidence interval {C

240 ; dERR, 0.51 [95% CI, .50-.52]), mebendazole-ivermectin (RR, 3.37 [95% CI, 2.20-5.16]), and tribendim

241 While ivermectin's activity against SARS-CoV-2 is currently un

242 Our results further extend ivermectin's broad antiviral activity and provide a mech

243 table, can likely reliably be used to assess ivermectin's mosquitocidal efficacy.

244 er of coinfected individuals at risk of post-ivermectin SAEs in West and Central Africa from 1995 to

245 Therefore, the GluCl-alpha2 subunit confers ivermectin sensitivity and a high-affinity desensitizing

246 We propose a model in which ivermectin sensitivity in C. elegans is mediated by gene

247 macrofilaricidal and sterilizing effects of ivermectin should be incorporated into transmission mode

248 ons higher than anthelmintic concentrations, ivermectin shows antiviral, antimalarial, antimetabolic,

249 Albendazole plus ivermectin significantly reduced prevalence of elephanti

250 A single ivermectin (standard) dose clears the skin-dwelling micr

251 GluCl, which was simulated in the absence of ivermectin starting from the structure with bound iverme

252 vitro incubation of adult P. univalens with ivermectin suggesting that drug-induced upregulation is

253 in B. pahangi-infected gerbils treated with ivermectin, suggesting that the loss of circulating micr

254 stic knowledge of ivermectin by showing that ivermectin targets the ability of importin-alpha (Imp-al

255 ation, significantly more patients receiving ivermectin than patients receiving vehicle control were

256 After ivermectin therapy was introduced (during 1988-2001), on

257 antifilarial antibody levels decreased after ivermectin therapy, none of these parameters was useful

258 ld studies have highlighted the potential of ivermectin to control malaria parasite transmission if t

259 e first report on structural modification of ivermectin to produce dual-action molecular hybrids with

260 frequently repeated mass administrations of ivermectin to village residents would reduce clinical ma

261 rly provides a safe strategy for large-scale ivermectin treatment and overcomes a major obstacle to t

262 344 (2.1%) individuals were excluded from ivermectin treatment because of a high L loa microfilari

263 mL) developing serious adverse events after ivermectin treatment during mass drug administration to

264 tentially practical approach to larger-scale ivermectin treatment for lymphatic filariasis and onchoc

265 Biannual ivermectin treatment improves the chances of reaching th

266 ogram cost, and program duration of biannual ivermectin treatment in different epidemiological and pr

267 The strategy of biannual ivermectin treatment in Ghana has reduced O. volvulus mi

268 t-treat strategy was used in the approach to ivermectin treatment in the Okola health district in Cam

269 ation of tissue inflammatory reactions after ivermectin treatment of onchocerciasis.

270 river blindness, remains challenging due to ivermectin treatment-associated adverse reactions in loi

271 ry model of neuropathic pain was reversed by ivermectin treatment.

272 ezuela that were recorded before introducing ivermectin treatment.

273 ication of villages warranting priority mass ivermectin treatment.

274 Onchocerca volvulus-infected subjects after ivermectin treatment.

275 al (mf) densities are low, such as following ivermectin treatment.

276 develop serious adverse events (SAEs) after ivermectin treatment.

277 ype-2 immune responses and eosinophilia post-ivermectin treatment.

278 ids, chloroquine and hydroxychloroquine, and ivermectin) under evaluation for COVID-19.

279 Loa loa microfilaraemia before being offered ivermectin (unless contraindicated).

280 tment, because of the high concentrations of ivermectin used in tissue-culture experiments.

281 Ivermectin, used to treat river blindness, binds in the

282 ious adverse events (SAEs) after exposure to ivermectin, using thresholds of >5,000 mf/ml and >30,000

283 Transport was reduced by PSC 833, ivermectin, verapamil, CSA, and vanadate, but not by leu

284 This effect of ivermectin was abolished in the mutant avr-15, which lac

285 cent derivatives of cyclosporine A (CSA) and ivermectin was concentrative, specific, and energy-depen

286 s, or 5% permethrin cream 7-14 days apart if ivermectin was contraindicated.

287 Ivermectin was extracted from the minced meat samples th

288 trict in Cameroon, where the distribution of ivermectin was halted in 1999 after the occurrence of fa

289 A single, 10-minute, at-home application of ivermectin was more effective than vehicle control in el

290 stration, particularly the administration of ivermectin, was efficacious for the control of scabies a

291 tin-dependent mitophagy inducer, the lactone ivermectin, we have combined genetic and imaging experim

292 s of abamectin, doramectin, eprinomectin and ivermectin were found in samples of bovine muscle and on

293 Responses to glutamate and ivermectin were inhibited by picrotoxinin and fipronil.

294 al aimed to assess whether multiple doses of ivermectin were superior to a single dose for the treatm

295 es of the insecticides nodulisporic acid and ivermectin were synthesized and demonstrated to bind wit

296 its sensitivity to the macrocyclic lactone, ivermectin, which allosterically modulates both ion cond

297 complex with the allosteric partial agonist ivermectin, which provided insights into the structure o

298 n that a single-dose, triple-drug treatment (ivermectin with diethylcarbamazine and albendazole [IDA]

299 sly recognized as responding suboptimally to ivermectin-with statistically significantly high microfi

300 anded use of albendazole in combination with ivermectin would ensure improved drug efficacies against